Every­one wants an ADC: GSK pays $85M up­front for ex-Chi­na rights to Han­soh Phar­ma's an­ti­body-drug con­ju­gate

MADRID — GSK has agreed to li­cense an an­ti­body-drug con­ju­gate from Han­soh Phar­ma for $85 mil­lion up­front, in ex­change for glob­al rights out­side of Chi­na, Hong Kong, Macau and Tai­wan.

The UK phar­ma promised an ad­di­tion­al $1.48 bil­lion in down­stream mile­stones, as well as tiered roy­al­ties on sales. The deal was an­nounced one day ahead of Han­soh’s pre­sen­ta­tion on an ear­ly-stage study of the drug HS-20089 in breast, ovar­i­an and en­dome­tri­al can­cer at ES­MO, the Eu­ro­pean can­cer con­fer­ence, in Madrid.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER